Osman A. Aksoy

Krems An Der Donau, 3500, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth.

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth.

Journal: Molecular cancer

Published: April 14, 2025

Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy.

Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy.

Journal: Expert opinion on therapeutic targets

Published: March 23, 2025

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.

Journal: Molecular oncology

Published: February 24, 2025

Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.

Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.

Journal: Journal for immunotherapy of cancer

Published: April 19, 2024

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Journal: Blood cancer journal

Published: April 13, 2024

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Journal: Molecular cancer

Published: March 23, 2023

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.

Journal: Expert opinion on pharmacotherapy

Published: July 13, 2022

Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.

Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.

Journal: Cytokine

Published: June 01, 2022

Emerging role of T3-binding protein μ-crystallin (CRYM) in health and disease.

Emerging role of T3-binding protein μ-crystallin (CRYM) in health and disease.

Journal: Trends in endocrinology and metabolism: TEM

Published: September 30, 2021

Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.

Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.

Journal: International journal of cancer

Published: July 23, 2020

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Journal: Nature communications

Published: October 27, 2015

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Journal: Nature communications

Published: March 08, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026